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ABSTRACT
Background In 2016 the first- in- human phase I study of 
a miRNA- based cancer therapy with a liposomal mimic of 
microRNA- 34a- 5p (miR- 34a- 5p) was closed due to five 
immune related serious adverse events (SAEs) resulting 
in four patient deaths. For future applications of miRNA 
mimics in cancer therapy it is mandatory to unravel the 
miRNA effects both on the tumor tissue and on immune 
cells. Here, we set out to analyze the impact of miR- 34a- 
5p over- expression on the CXCL10/CXCL11/CXCR3 axis, 
which is central for the development of an effective cancer 
control.
Methods We performed a whole genome expression 
analysis of miR- 34a- 5p transfected M1 macrophages 
followed by an over- representation and a protein–protein 
network analysis. In- silico miRNA target prediction and 
dual luciferase assays were used for target identification 
and verification. Target genes involved in chemokine 
signaling were functionally analyzed in M1 macrophages, 
CD4+ and CD8+ T cells.
Results A whole genome expression analysis of M1 
macrophages with induced miR- 34a- 5p over- expression 
revealed an interaction network of downregulated target 
mRNAs including CXCL10 and CXCL11. In- silico target 
prediction in combination with dual luciferase assays 
identified direct binding of miR- 34a- 5p to the 3′UTRs of 
CXCL10 and CXCL11. Decreased CXCL10 and CXCL11 
secretion was shown on the endogenous protein level 
and in the supernatant of miR- 34a- 5p transfected and 
activated M1 macrophages. To complete the analysis of 
the CXCL10/CXCL11/CXCR3 axis, we activated miR- 34a- 
5p transfected CD4+ and CD8+ T cells by PMA/Ionomycin 
and found reduced levels of endogenous CXCR3 and 
CXCR3 on the cell surface.
Conclusions MiR- 34a- 5p mimic administered by 
intravenous administration will likely not only be up- taken 
by the tumor cells but also by the immune cells. Our 
results indicate that miR- 34a- 5p over- expression leads in 
M1 macrophages to a reduced secretion of CXCL10 and 
CXCL11 chemokines and in CD4+ and CD8+ T cells to a 
reduced expression of CXCR3. As a result, less immune 
cells will be attracted to the tumor site. Furthermore, high 
levels of miR- 34a- 5p in naive CD4+ T cells can in turn 
hinder Th1 cell polarization through the downregulation of 
CXCR3 leading to a less pronounced activation of cytotoxic 
T lymphocytes, natural killer, and natural killer T cells and 
possibly contributing to lymphocytopenia.
BACKGROUND
Micro(mi)RNAs are small non- coding RNA 
molecules of ~21–24 nucleotides (nt) in 
length and function as post- transcriptional 
regulators of gene expression.1 The specific 
binding of miRNAs to target sites, mostly in 3′ 
untranslated regions (3′UTRs) of their target 
mRNAs, leads to an inhibition of the synthesis 
of the target proteins.2 In few cases miRNAs 
can bind within 5′ untranslated regions or 
open reading frames.3 MiRNAs play a pivotal 
role in carcinogenesis as shown for a variety 
of cancer types.4 Among the most prominent 
tumor related miRNAs, tumor suppressor 
miR- 34a- 5p is lost or downregulated in broad 
range of cancer types.5–7 In 2013 a clinical 
trial (NCT01829971) with a liposomal miR- 
34a- 5p mimic (MRX34) has been started 
for patients with unresectable primary liver 
cancer, advanced liver cancer, or metastatic 
liver cancer. In 2016 the phase I of this 
study was stopped due to immune- mediated 
serious adverse events (SAEs) leading to 
death of four patients.8 At the same time, 
there was first evidence for increased levels 
of miR- 34a- 5p in the serum or whole blood 
of cancer patients.9 10 A later study demon-
strated an upregulation of miR- 34a- 5p in 
different blood cells including monocytes, 
natural killer cells, B cells and CD3+ T cells 
of patients with lung cancer.11 We recently 
provided evidence for a role of miR- 34a- 5p in 
T cell signaling and in the formation of the 
immunological synapse.12 A network- based 
approach revealed a functional role of miR- 
34a- 5p in intracellular calcium signaling and 
in NF-κB signaling as part of T cell regulation 
networks.13–15 Here, we set out to investigate 
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the role of miR- 34a- 5p in chemokine signaling, which is 
central for orchestrating a directed antitumor- response.
METHODS
Cell lines, tissue culture
Human HEK 293T cells were purchased from the German 
collection of micro- organisms and cell cultures (DSMZ) 
and authenticated using STR DNA typing. HEK 293T 
cells were cultured as described previously.12 The cell line 
was cultured for less than 6 months after receipt.
Isolation and differentiation of macrophages
M1 macrophages were differentiated from freshly 
obtained PBMC using M1 macrophage Generation 
Medium DXF according to the manufacturer’s protocol 
(PromoCell GmbH, Heidelberg, Germany). In brief, 
freshly isolated PBMCs were seeded out in an appropriate 
amount of Monocyte Attachment Medium (C-28051, 
PromoCell GmbH) in a density of 1 million/cm2 and 
incubated for 1–1.5 hours at 5% CO2, 37°C. Subsequently, 
the non- adherent cells were removed by three washing 
steps with warm monocyte attachment medium, the M1 
macrophage Generation Medium DXF (C-28055, Promo-
Cell GmbH) was added to the remaining adherent mono-
cytes and the cells were incubated with refreshment of the 
M1 macrophage Generation Medium DXF every 3 days 
for 9 days at 5% CO2 and 37°C. At day 10, the differen-
tiated M1- Macrophages were checked by flow cytometry 
for correct differentiation, transfected as described below 
and used for the mRNA microarrays and ELISAs.
mRNA microarray
For detection of mRNA expression changes in activated 
and miR- 34a- 5p transfected M1 macrophages the Agilent 
Low Input, one- color, Quick Amp Labeling Kit and Sure-
Print G3 Human Gene Expression 8×60Kv3 Microarray 
(Cat. No. G4851C, Agilent Technologies, Santa Clara, 
California, USA) was used corresponding to the manu-
facturer’s protocols. In brief, 100 ng total RNA was 
reversed transcribed at 40°C for 2 hours using T7 Primer. 
Subsequently, the cRNA was labeled with Cyanine3- pCp 
using the T7 RNA polymerase for 2 hours at 40°C. The 
purification of the labeled cDNA was performed with 
RNeasy Mini kit (Qiagen, Hilden, Germany) according 
to Agilent’s One- Color Gene Expression Microarray 
Protocol followed by the quantification using a Nano-
Drop2000 Spectrophotometer (Thermo Fisher Scientific, 
Waltham, Massachusetts, USA). The hybridization of 
600 ng labeled cRNA to the microarray slide was carried 
out at 65°C, 17 hours, 10 rpm in the SureHyb chambers 
(Agilent Technologies). After two washing steps the 
microarray slide was scanned on the Agilent Microarray 
Scanner G2565BA (Agilent Technologies). The raw fluo-
rescence signals were analyzed with the Agilent AGW 
Feature Extraction software (V.10.7.1.1, Agilent Tech-
nologies). Normalization of the background corrected 
values was done with the Biological Significance analysis 
using GeneSpring (V.14.9, Agilent Technologies). In our 
analysis only mRNAs with RefSeqAccession number were 
included that were detected in at least four of the tested 
samples. The fold change of the mRNAs from miR- 34a- 5p 
transfected M1- macrophages was calculated by normal-
ization of the expression values to the mean expression 
values of the control samples.
Expression and reporter vectors
The pSG5- mir- 34a expression plasmid was synthesized 
and cloned by Eurofins Genomics and harbors the 
nucleotides 9151617-9151816 of chromosome 1 (Euro-
fins Genomics). The 3′UTRs of CXCR1, CXCR2, CXCR3, 
CXCL1, CXCL2, CXCL5, CXCL10, CXCL11, CXCL12, 
CXCL14, and CXCL16 were PCR amplified using specific 
primers and ligated via SpeI, SacI, or NaeI restriction sites 
into the pMIR- RNL- TK vector, which was described in 
Beitzinger et al.16 The target sites of positively tested target 
genes were mutated using specific primers by site- directed 
mutagenesis with the QuickChange II Site- Directed Muta-
genesis Kit (Agilent Technologies). The sequences of all 
specific cloning and mutagenesis primers are given in 
online supplemental tables 1 and 2.
Dual luciferase reporter assays
The dual luciferase assays were performed as described 
previously.17 In brief, HEK 293T cells were seeded out 
and transfected after 24 hours with the respective combi-
nations of reporter and expression vectors. PolyFect 
transfection reagent (Qiagen) was used for the tran-
sient transfections and the Dual- Luciferase Reporter 
Assay System Kit (Promega, Mannheim, Germany) for 
conducting the dual luciferase assays. All dual lucif-
erase assays were conducted in duplicates and have been 
repeated four times.
CD4+ and CD8+ T cell isolation, transfection, stimulation, flow 
cytometry, and western blot analysis of CD4+ and CD8+ T cells
CD4+ or CD8+ T cells were isolated, purity was confirmed, 
and the cells were cultured as described previously.15 17 
The gating strategy for the CD4+ and CD8+ T cells is shown 
in online supplemental figure 1. CD4+ and CD8+ T cells 
were transfected with hsa- miR- 34a- 5p miScript miRNA 
Mimic (MIMAT0000255: 5′ UGGC AGUG UCUU AGCU 
GGUUGU) or the allstars negative control (ANC) using 
HiPerFect transfection reagent (Qiagen) as mentioned 
earlier.15 Twenty- four hours post transfection CD4+ and 
CD8+ T cells were stimulated with PMA/Ionomycin 
(5 ng/500 ng) for 24 hours. After stimulation, 1×105 of 
the transfected CD4+ and CD8+ T cells were stained with 
anti- CD4- FITC (RPA- T4, BD), anti- CD8- FITC (RPA- T8, 
BD) and anti- CXCR3- APC (1C6/CXCR3 (RUO), BD) or 
respective conjugated isotype control antibodies, fixed 
in 1% paraformaldehyde and analyzed by flow cytometry 
(FACS Canto II, BD Biosciences). The remaining trans-
fected CD4+ and CD8+ T cells were used for western blot 
analysis, performed as described previously.15 CXCR3 was 
stained with a monoclonal rabbit anti human CXCR3 
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antibody (6H1L8, Thermo Fisher Scientific). α-tubulin 
served as loading control and was stained with a mono-
clonal rabbit anti human α-tubulin antibody (11H10, Cell 
Signaling Technology). The secondary antirabbit anti-
body was purchased from Sigma Aldrich (A0545, Sigma 
Aldrich).
Quantification of CXCL10 and CXCL11 secretion by ELISA and 
endogenous levels of CXCL10 and CXCL11 by western blot 
analysis
1.5×106 differentiated macrophages of two donors/
mL/12well were transfected with 150 ng hsa- miScript 
miRNA Mimic miR- 34a- 5p (MIMAT0000255: 
5′UGGCAGUGUCU UAGCUGGUUGU) or the ANC 
using HiPerFect transfection reagent (Qiagen). The 
transfections were carried out in three independent 
experiments from two donors. After 48 hours of trans-
fection the M1 macrophages were activated using IFN-γ 
(50 ng/mL, Miltenyi Biotec) and LPS (10 ng/mL, Sigma 
Aldrich). Four hours after activation the supernatants 
of the transfected M1 macrophages were collected and 
CXCL10 as well as the CXCL11 secretion was quantified 
by the human CXCL10 or CXCL11 DuoSet ELISA Kit 
(R&D Systems) according to manufacturer’s protocol. 
The remaining M1 macrophages were stored in 700 µL 
Qiazol (Qiagen) at −80°C for subsequent RNA isolation.
After 48 hours following transfection, the M1 macro-
phages were activated using IFN-γ (50 ng/mL, Miltenyi 
Biotec) and LPS (10 ng/mL, Sigma Aldrich) for 20 hours. 
After stimulation, 1.5×106 of the transfected M1 macro-
phages were used for western blot analysis, performed as 
described previously.15 CXCL10 was stained with a mono-
clonal rabbit anti human CXCL10 antibody (D5L5L, 
Cell Signaling Technology). CXCL11 was stained with a 
monoclonal mouse anti human CXCL11 antibody (10C6, 
Thermo Fisher Scientific). α-tubulin served as loading 
control and was stained with a monoclonal rabbit anti 
human α-tubulin antibody (11H10, Cell Signaling Tech-
nology). All secondary antibodies were purchased from 
Sigma Aldrich.
RNA-isolation, quantitative real time PCR
48 hours post transfection of ANC or miR- 34a- 5p into 
1.5×106 macrophages of two donors RNA isolation was 
conducted using the miRNeasy Mini Kit according to 
the manufacturer’s protocol (Qiagen). The levels of hsa- 
miR- 34a- 5p in the transfected M1 macrophages was deter-
mined by quantitative real time PCR (qRT- PCR) using the 
StepOnePlus Real- Time PCR System (Applied Biosystems, 
Foster City, USA) and the miScript PCR System (Qiagen) 
corresponding to the manufacturer’s protocols. In brief 
200 ng total RNA was reverse transcribed into cDNA using 
the miScript RT II Kit with the miScript HiSpec Buffer 
(Qiagen). RNU6 served as endogenous control for 
miRNA expression. Ectopic expression of miR- 34a- 5p in 
M1 macrophages of the two donors is depicted in online 
supplemental figure 2.
Data analysis and web tools
Statistical analysis of the luciferase assays, the western 
blots, the FACS analysis and ELISA was performed with 
SigmaPlot 10 (Systat, Chicago, USA) applying Student’s 
t- test. Quantification of the western blots was carried out 
with Image Lab Software V.5.2.1 (Bio- Rad Laboratories, 
Hercules, California, USA). The asterisks in the figures 
correspond) to the statistical significance as calculated 
by Student’s t- test: *=0.01< p≤0.05; **=0.001<p≤0.01; 
***=p≤0.001. For the pathway analysis of the deregu-
lated mRNAs and predicted target genes by an over- 
representation analysis (ORA), we used GeneTrail3 using 
default settings (Null hypothesis (for p value computa-
tion): two- sided; method to adjust p values: Benjamini- 
Yekutieli; significance level: 0.05; reference set: all protein 
coding genes) (http:// genetrail. bioinf. uni- sb. de/).18 For 
the protein–protein interaction network analysis we used 
the STRING database V.11 (https:// string- db. org/) with 
default settings including the 20 most downregulated 
and upregulated mRNAs on miR- 34a- 5p over- expression 
to obtain a concise network.19 The in- silico target predic-
tion was carried out using miRWalk 2.0 that uses 10 algo-
rithms including DIANAmT3.0, miRanda (2010), miRDB 
(2009), miRWalk, RNAhybrid (V.2.1), PICTAR4 (2006), 
PICTAR5 (2007), PITA (2008), RNA22 (2008), and 
TargetScan5.1.20
RESULTS
Analysis of differentially expressed mRNAs in M1 
macrophages upon miR-34a-5p over-expression
In a former study we found miR- 34a- 5p over- expressed 
in CD56+ (natural killer cells), CD19+ (B cells), CD3+ 
(T cells) as well as CD14+ (monocytes) cells of patients 
with lung cancer.11 Subsequently, we identified miR- 
34a- 5p as modulator of intracellular calcium signaling, 
NF-κB signaling in CD4+/CD8+ T cells and as major hub 
of T cell regulation networks.13 15 17 Here we set out to 
investigate the impact of miR- 34a- 5p over- expression on 
chemokine signaling by analyzing the mRNA expression 
changes in the M1 macrophages transfected with miR- 
34a- 5p or ANC from two different donors of two inde-
pendent transfection experiments (figure 1A). Out of 58 
000 mRNAs contained in the Agilent microarray, 27 285 
transcripts were detected in at least four out of the eight 
samples. In total, 480 protein- coding transcripts showed 
an at least 1.5- fold change in the miR- 34a- 5p transfected 
cells as compared with the control cells. Out of the 480 
mRNAs, 184 were upregulated and 296 downregulated. 
An ORA of 480 deregulated mRNAs by GeneTrail3 iden-
tified 140 significant pathways in Gene Ontology (GO) 
category “biological process” and 12 significant pathways 
in the GO category “molecular function” for the down-
regulated mRNAs. Figure 1B,C displays a representative 
selection of the significant pathways of these two GO cate-
gories. For example, the five most significant pathways 
in the GO category “molecular function” were “cytokine 
activity” (p value ≤0.001), “cytokine receptor binding” (p 
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value ≤0.001), “type I interferon receptor binding” (p 
value ≤0.001), “receptor ligand activity” (p value ≤0.001), 
and “signaling receptor activator activity” (p value 
≤0.001). For the upregulated mRNAs only one signif-
icant pathway, GO molecular function: “nucleic acids 
binding” was detected. Online supplemental tables 3 and 
4 summarize the complete results of the ORA analysis for 
the downregulated and upregulated mRNAs. To identify 
protein–protein interaction networks we conducted a 
protein–protein association analysis using the STRING 
database with the 20 most downregulated and upregu-
lated mRNAs on miR- 34a- 5p over- expression applying 
an interaction score of ≥0.4. This analysis highlighted 
a central interaction network for the downregulated 
mRNAs consisting of IFNA16, IFNA4, IFNB1, INFL1, IL6, 
CXCL10, and CXCL11 (figure 1D). For the upregulated 
mRNAs no interaction network could be established 
(figure 1E).
C-X-C motif ligands and C-X-C motif receptors are predicted 
target genes of miR-34a-5p
To explore the function of miR- 34a- 5p in the regulation 
of the immune response via cytokines, we performed a 
combination of in- silico target prediction with down-
stream pathway analysis to identify potential miR- 34a- 5p 
target genes. First, we conducted an in- silico target 
prediction by miRWalk V.2.0. In total, we identified 57 373 
potential target gene 3′UTRs of miR- 34a- 5p (figure 2A). 
We subsequently reduced the number of putative target 
genes to 12 802 by considering only target gene 3′UTRs, 
Figure 1 Gene expression analysis of the effects of miR- 34a- 5p over- expression in M1 macrophages. (A) Experimental 
workflow. (B- C) Over- representation analysis of 296 mRNAs, which were at least 1.5- fold downregulated on miR- 34a- 5p 
over- expression by GeneTrail3. (B) Representative significant enriched pathways in Gene Ontology (GO) category “biological 
process.” (C) Representative significant enriched pathways in the GO category “molecular function.” (D) Protein–protein 
interaction networks of the 20 most downregulated mRNAs using the STRING database V.11 (https://string-db.org/). (E) Protein–
protein interaction networks of the 20 most upregulated mRNAs using the STRING database V.11.
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Figure 2 (A) Workflow for the prediction and pathway analysis of miR- 34a- 5p target genes associated with chemokine 
signaling. (B) mRNA expression changes of C- X- C motif ligands on miR- 34a- 5p over- expression. Blue color represents a log2 
fold change ≤−0.2. (C) mRNA expression changes of C- X- C motif receptors on miR- 34a- 5p over- expression.
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which were predicted by at least four different algorithms. 
To identify potential miR- 34a- 5p target genes related to 
chemokine signaling, we mapped the predicted target 
genes to the according pathways by GeneTrail3 and iden-
tified 655 significant pathways. Out of these pathways, 38 
significant pathways belonged to GO Cellular Compo-
nent, 16 to GO Molecular Function, 79 to Wiki Path-
ways, 146 to KEGG (Kyoto Encyclopedia of Genes and 
Genomes), and 375 to GO biological processes. The GO 
biological process category included the three significant 
pathways, “chemokine mediated signaling pathway” with 
75 potential miR- 34a- 5p target genes, “positive regulation 
of chemotaxis” with 107 and “positive regulation of leuko-
cyte migration” with 90 potential target genes. We subse-
quently deleted target genes, which have been validated 
by others according to miRTarBase21 and genes without 
canonical binding site for miR- 34a- 5p. Following these 
selection steps, we identified eight C- X- C motif ligands 
and three C- X- C motif receptors with miR- 34a- 5p binding 
sites in their 3′UTRs in the three pathways that is, “chemo-
kine mediated signaling pathway,” “positive regulation of 
chemotaxis,” and “positive regulation of leukocyte migra-
tion.” The C- X- C motif ligands included CXCL1, CXCL2, 
CXCL5, CXCL10, CXCL11, CXCL12, CXCL14, CXCL16 
and the C- X- C motif receptors included CXCR1, CXCR2, 
CXCR3.
REGULATION OF C-X-C MOTIF LIGANDS AND C-X-C MOTIF 
RECEPTORS MRNAS UPON MIR-34A-5P OVER-EXPRESSION IN 
M1 MACROPHAGES
Table 1 displays the 20 most upregulated or downregu-
lated mRNAs in the miR- 34a- 5p transfected M1 macro-
phages including CXCL10 and CXCL11. Among the 
mRNAs encoding CXCLs and CXCRs with miR- 34a- 5p 
binding sites in their 3′UTRs, the mRNAs for CXCL10, 
CXCL11, and CXCR3 showed the strongest decrease in 
mRNA expression on miR- 34a- 5p over- expression. In 
detail, CXCL11 mRNA showed a median log2 fold change 
of −1.75, CXCL10 mRNA a change of −1.3, and CXCR3 a 
change of −0.295 (figure 2B,C, online supplemental table 
5).
C-X-C motif ligands and C-X-C motif receptors as miR-34a-5p 
targets identified by dual luciferase assays
Our in- silico target prediction identified eight C- X- C 
motif ligands and three C- X- C motif receptors with miR- 
34a- 5p binding sites in their 3′UTRs including CXCL1, 
CXCL2, CXCL5, CXCL10, CXCL11, CXCL12, CXCL14, 
CXCL16 as well as CXCR1, CXCR2, CXCR3 (figure 3). 
We cloned the respective 3′UTR sequences into the pMIR- 
RNL- TK reporter vector and cotransfected these recom-
binants together with a miR- 34a- 5p expression vector in 
HEK 293T cells. Dual luciferase assays were conducted in 
duplicates and repeated four times. The luciferase activi-
ties (RLU (relative light units)) of the wild- type reporters 
were normalized against the RLU of the empty reporter 
vector. Among the C- X- C motif ligands, we found the 
Table 1 20 most upregulated and downregulated mRNAs 
in miR- 34a- 5p transfected M1 macrophages. Upper panel 
displays the 20 most downregulated mRNAs and the lower 
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strongest reduction of the RLU for CXCL11, which was 
reduced to 66.3% (p value ≤0.001). Except for the ligands 
CXCL2 and CXCL5, all other remaining C- X- C ligands 
were also significantly repressed by miR- 34a- 5p including 
CXCL14 (67.4%), CXCL1 (70.4%), CXCL10 (70.5%), 
CXCL16 (82.6%), and CXCL12 (83.3%) (figure 4A, left 
panel). Among the C- X- C motif receptors, we observed 
the strongest reduction of the RLU for CXCR3, which 
was reduced to 76.5% (p value ≤0.001). The remaining 
C- X- R receptors were also significantly repressed by miR- 
34a- 5p including CXCR1 (86%) and CXCR2 (88.5%) 
(figure 4A, right panel). To validate the direct binding of 
miR- 34a- 5p to its target sites, we mutated the binding sites 
in the 3′UTRs of CXCL ligands CXCL1, CXCL10, CXCL11, 
CXCL14, CXCL16 and in the 3′UTRs of CXCR recep-
tors CXCR1 and CXCR3. Except for CXCR1, all mutated 
reporter vectors showed a significant increase of the RLU 
when cotransfected with miR- 34a- 5p compared with the 
respective non- mutated recombinants indicating the 
direct binding of miR- 34a- 5p to its binding sites in the 
respective 3′UTRs (figure 4B).
MiR-34a-5p over-expression decreased CXCR3 levels in CD4+ 
and CD8+ T cells as well as CXCL10 and CXCL11 levels in M1 
macrophages
To analyze the downstream effects of miR- 34a- 5p over- 
expression in immune cells, we focused on the CXCL10/
CXCL1/CXCR3 axis, which is central for the develop-
ment of an effective cancer control, the differentiation of 
naive T cells to T helper 1 (Th1) cells, and the direction 
of immune cells to their functional sites by a chemotactic 
gradient of the chemokines CXCL9, CXCL10, CXCL11 
binding to CXCR3.22–24
We transfected CD4+ and CD8+ T cells with miR- 34a- 5p 
mimic or with “ANC” and activated the transfected T cells 
for 4 hours with PMA/Ionomycin 48 hours after transfec-
tion. Western blotting with an antibody directed against 
CXCR3 showed a reduction of endogenous CXCR3 
protein to 67.4% in the miR- 34a- 5p transfected CD4+ T 
cells (p value ≤0.001) and to 33.2% in the miR- 34a- 5p 
transfected CD8+ T cells (0.01<p≤0.05) (figure 5A,B). 
Flow cytometry was used to analyze the effect of miR- 
34a- 5p over- expression on CXCR3 cell surface expres-
sion. Following transfection and activation, we found a 
downregulation of CXCR3 cell surface expression to 
56.4% in miR- 34a- 5p transfected CD4+ T cells (p value 
0.001<p≤0.01) and to 2.5% in miR- 34a- 5p transfected 
CD8+ T cells compared with control transfected cells (p 
value ≤0.001) (figure 5C–G).
We next investigated the effect of miR- 34a- 5p on the 
CXCL10, CXCL11 secretion and the endogenous levels 
in M1- macrophages, which were recently identified to 
predominantly express CXCL10, and CXCL11 after 
immune checkpoint blockade.25 We differentiated mono-
cytes in M1 macrophages, transfected the cells with miR- 
34a- 5p mimics or with ANC, and activated the transfected 
cells with IFN-γ and LPS. Western blot analysis of three 
independent experiments from two different donors 
with antibodies against CXCL10 and CXCL11 showed 
a decrease of endogenous CXCL10 protein to 57.9% 
(p value ≤0.001) on miR- 34a- 5p over- expression and of 
endogenous CXCL11 protein to 52.6% (0.01<p≤0.05) 
(figure 6A,B). Using ELISA we found in three indepen-
dent experiments from two different donors a reduced 
CXCL10 secretion to 69.3% (p value ≤0.001) and a 
reduced CXCL11 secretion to 59.2% (p value ≤0.001) in 
the supernatants of miR- 34a- 5p transfected M1 macro-
phages (figure 6C).
DISCUSSION
We determined the role of miR- 34a- 5p in chemokine 
signaling and identified miR- 34a- 5p as key modulator of 
the CXCL10/CXCL11/CXCR3 axis. This axis is central 
for the development of an effective cancer control as 
recently summarized in a review by Tokunaga et al.22 A 
single cell RNA- seq analysis of tumor- infiltrating immune 
cells after immune checkpoint blockade showed that 
CXCL10 is predominantly expressed by macrophages.25 
CXCL10 is induced by IFN-γ, IFN-α/β, and regulated 
by NF- kB.26 27 In response to IFN-γ, CXCL10 is secreted 
by monocytes, endothelial cells, fibroblasts, and cancer 
cells.28 First evidence for a direct impact of the interplay 
between miR- 34a- 5p and CXCL10 on the tumor devel-
opment stems from a study showing that the inhibition 
of CXCL10 by miR- 34a- 5p in breast cancer cells leads 
to a suppression of invasion and migration.29 Further 
evidence for a central role of CXCL10 in tumor devel-
opment stems from studies on murine malignant pleural 
effusion (MPE) models. The intrapleural injection of 
CXCL10- deficient tumor cells resulted in a decrease of 
Th1 and Th17 cells in MPE, an increase of MPE volume, 
and a reduction of survival.30 Our analysis shows that the 
CXCL10 secretion can be reduced by miR- 34a- 5p over- 
expression in M1 macrophages suggesting differential 
roles of miR- 34a- 5p in cancer and immune cells.
The second ligand CXCL11, which is regulated by 
miR- 34a- 5p can also be induced by IFN-γ and IFN-β.31 
CXCL11 has the highest affinity to the CXCR3 chemo-
kine receptor of the three selective ligands followed 
by CXCL10 and CXCL9.32 33 Like CXCL10, CXCL11 is 
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Figure 3 Schematic diagram of reporter gene plasmids. The position of the predicted miR- 34a- 5p binding sites in the 
respective 3′UTR reporter plasmids and their corresponding sequences as well as the sequences of the mutated binding sites 
(underlined) are shown. (A) CXCL1-3′UTR reporter vector, (B) CXCL2-3′UTR reporter vector, (C) CXCL5-3′UTR reporter vector, 
(D) CXCL10-3′UTR reporter vector, (E) CXCL11-3′UTR reporter vector, (F) CXCL12-3′UTR reporter vector, (G) CXCL14-3′UTR 
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cells, fibroblasts, and cancer cells.28 Cancer cell secreted 
CXCL11 can promote CD8+ T cells infiltration in non- 
small lung cancer by docetaxel treatment.34 CXCL11 as 
genetic adjuvant increase vaccine antigen- specific CD8+ 
T cells to a greater degree than the other two CXCR3 
ligands.35
Like the ligands, the miR- 34a- 5p regulated receptor 
CXCR3 plays a pivotal role in tumor development. 
CXCR3 is strongly expressed on activated Th1 cells, cyto-
toxic T lymphocytes (CTLs), natural killer (NK) cells, and 
natural killer T (NKT) cells.36 On naive T cells CXCR3 is 
downregulated but rapidly induced by antigen- presenting 
Figure 4 (A) Dual luciferase reporter gene assays. Left panel: dual luciferase reporter gene assays of C- X- C motif ligands, 
right panel: dual luciferase reporter gene assays of C- X- C motif receptors. HEK 293T cells were cotransfected with miR- 
34a- 5p and reporter vectors of the target genes as indicated. The luciferase activities were normalized with respect to the 
luciferase activity measured with empty reporter construct. The results represent the mean of four independent experiments 
carried out in duplicates. Columns colored in turquois represent a significant reduction of the luciferase activity with a p value 
≤0.001. Columns colored in magenta represent a significant reduction of the luciferase activity with a p value ≤0.01 and ≥0.001. 
Columns colored in dark blue represent a non- significant reduction of the luciferase activity with a p value ≥0.05. Data are 
represented as mean±SEM, (B) dual luciferase reporter gene assays with mutated reporter constructs, left panel: dual luciferase 
reporter gene assays of mutated C- X- C motif ligand constructs, right panel: dual luciferase reporter gene assays of mutated C- 
X- C motif receptor constructs. HEK 293T cells were cotransfected with the miR- 34a- 5p and the wild type reporter plasmids of 
the respective target genes or mutated reporter plasmids (mut) of the respective target genes as indicated in the diagram. The 
luciferase activities were normalized with respect to the luciferase activity measured with empty reporter construct. Columns 
colored in turquois represent a significant induction of the luciferase activity of the respective mutated reporter vector with a 
p value ≤0.001. Columns colored in dark blue represent a non- significant induction of the luciferase activity of the respective 
mutated reporter vector with a p value ≥0.05. Data are represented as mean±SEM. RLU, relative light units.
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Figure 5 Effect of miR- 34a- 5p over- expression on CXCR3 of CD4+ and CD8+ T cells. (A) Western blot analysis of CXCR3 
in miR- 34a- 5p transfected CD4+ (left panel) and CD8+ T cells (right panel). The cells were transfected either with allstars 
negative control (ANC) or miR- 34a- 5p mimic. 48 hours after transfection the cells were activated using PMA/ionomycin and 
the endogenous protein level of CXCR3 was analyzed by western blotting using specific antibodies against CXCR3. α-tubulin 
served as loading control. One representative western blot is displayed. (B) Quantification of endogenous CXCR3 protein levels 
in miR- 34a- 5p transfected CD4+ (left panel) and CD8+ T cells (right panel). Three independent western blots were quantified 
by densitometry using image lab software. The protein expression of CXCR3 in CD4+ and CD8+ T cells was normalized 
with respect to the corresponding α-tubulin signals of the appropriate samples. The three asterisks correspond to a p value 
≤0.001 and one asterisk to a p value 0.01<p≤0.05. (C) CD4+ T cells were stained for CD4 and costained for CXCR3 for 30 min at 
4°C. Cells were analyzed by flow cytometry. gated CD4+ T cells were analyzed for CXCR3 expression. (D) Mean fluorescence 
intensities of CXCR3 of CD4+ T cells. ANC- transfected (red) or miR- 34a- 5p mimic- transfected (blue) CD4+ T cells or respective 
isotype controls (green and gray) were analyzed by flow cytometry. (E) CD8+ T cells were stained for CD8 and costained for 
CXCR3 for 30 min at 4°C. Cells were analyzed by flow cytometry. Gated CD8+T cells were analyzed for CXCR3 expression. 
(F) Mean fluorescence intensities of CXCR3 of CD8+ T cells. ANC- transfected (red) or miR- 34a- 5p mimic- transfected (blue) 
CD8+ T cells or respective isotype controls (green and gray) were analyzed by flow cytometry. (G) Quantification of cell surface 
levels of CXCR3 on miR- 34a- 5p transfection on CD4+ and CD8+ T cells. FACS data from four independent experiments from 
two different donors performed in duplicates were summarized. ANC transfected control is displayed in black and miR- 34a- 5p 
transfected T cells in gray. Two asterisks correspond to a p value ≤0.01 and ≥0.001 and three asterisks to a p value ≤0.001. Data 
are represented as mean±SEM.
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dendritic cells causing Th1 polarization following Th1 
dependent activation of CTLs, NK, and NKT cells by 
INF-γ.37 In humans three isoforms of CXCR3 CXCR3- A, 
CXCR3- B, and CXCR3- Alt were identified exhibiting 
differences in ligand- binding properties, signaling path-
ways, and cellular responses.38 In a murine lung cancer 
model IL-7 induces antitumor reactivity of T cells in a 
CXCR3 ligand dependent manner.39
To fully appreciate the role of miR- 34a- 5p in tumor 
development, it is necessary to consider its impact on 
the entire CXCL10/CXCL11/CXCR3 axis. The axis 
primarily mediates migration, differentiation, and activa-
tion of immune cells. The paracrine CXCL10/CXCL11/
CXCR3 signaling in tumor models displays antitumor 
activity mediated by Th1, CTLs, NK, and NKT cells.40 
The autocrine CXCL10/CXCL11/CXCR3 axis in cancer 
cells increases proliferation, angiogenesis, and metas-
tasis. Former studies showed that CXCR3+ cancer cells 
have a disposition to migrate to ligand rich metastatic 
sites.41 42 Specific aspects of this axis in cancer are contro-
versially discussed as for example the association between 
CXCL10 and poor prognosis.43 44 Nevertheless, the auto-
crine and the paracrine signaling offers the possibility 
for cancer treatment by activating the paracrine axis and 
inhibiting the autocrine signaling.22 An immunotherapy 
may combine ectopic expression of CXCL10/CXCL11 
Figure 6 (A–C) Effects of miR- 34a- 5p over- expression on the endogenous levels and secretion of CXCL10 and CXCL11 in M1 
macrophages. Monocytes were differentiated in M1 macrophages, transfected with ANC, or miR- 34a- 5p mimic, and activated 
with IFN-γ and LPS. Subsequently, the CXCL10 and CXCL11 endogenous levels were measured by western blots (A, one 
representative western blot is displayed) and quantified from three independent experiments from two different donors (B) Three 
asterisks correspond to p value ≤0.001 and one asterisk to a p value 0.01<p≤0.05. The secretion was measured by ELISA (C). 
ELISA data were quantified from three independent experiments from two different donors. Three asterisks correspond to p 
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in the tumor, for example, by intratumor injections of 
CXCL1045 and the inhibition of CXCR3 on cancer cells, 
for example, by CXCR3 antagonists (like AMG487).42 
With regard to immune cells, our results indicate that 
over- expression of miR- 34a- 5p in CD4+, CD8+ T cells, and 
M1 macrophages can impact the antitumor- response. 
Due to miR- 34a- 5p over- expression, M1 macrophages 
synthesize and secret less CXCL10 and CXCL11 chemo-
kines and CD4+ and CD8+ T cells synthesize and express 
less CXCR3 on their surface. Hence, it can be assumed 
that far fewer immune cells will be attracted to the tumor 
site (figure 6D). Taken together with the results of our 
former studies that showed a downregulation of VAMP2 
expression and PRF1 secretion together with a reduced 
killing efficiency of miR- 34a- 5p over- expressing CD8+ T 
cells, our data provide strong evidence that miR- 34a- 5p 
over- expression will not solely impact the chemotaxis but 
also their effector functions at the tumor site.14 15
Our data on the effect of miR- 34a- 5p in immune cells 
may also help to explain the immune related SAEs, 
especially the lymphocytopenia observed with patients 
that have undergone the immunotherapy with MRX34. 
It is very likely that the miR- 34a- 5p mimic, which was 
administered by intravenous administration was not only 
up- taken by the tumor cells but also by the immune cells. 
High levels of miR- 34a- 5p in naive CD4+ T cells can in 
turn hinder Th1 polarization through the downregula-
tion of CXCR3 leading to a less pronounced activation of 
CTLs, NK and NKT cells. In addition, elevated levels of 
miR- 34a- 5p in CD4+ and CD8+ T cells also impact central 
components of the intracellular calcium signaling and the 
NF-κB signaling and are associated with a decreased CD8+ 
mediated killing efficiency in the tumor microenviron-
ment.13 14 Consequently, intravenously administered miR- 
34a- 5p mimic may cause immune related SAEs including 
lymphocytopenia by several cellular routes.
To limit off target effects in immune cells, it is necessary 
to allow a directed and specific delivery of miR- 34a- 5p to 
the tumor cells. As shown for multiple myeloma the miR- 
125b- dependent stimulation of miR- 34a- 5p expression via 
the IL- 6R/STAT3/miR- 34a feedback loop offers a possi-
bility to increase miR- 34a- 5p- levels in tumor cells while 
avoiding off target effects in immune cells.46 Another 
possibility for a directed delivery is to encapsulate the 
miR- 34a-5- p mimic in nanocarriers. Former studies used 
stable nucleic acid lipid vesicles (SNALPs) encapsulating 
miR- 34a- 5p for the treatment of multiple myeloma cells.47 
These SNALPs were conjugated with transferrin to target 
multiple myeloma cells that overexpress transferrin 
receptors. This ensured an efficient delivery to these cells 
in an in vivo mouse model avoiding evident toxicity and 
prolonging the survival of the miR- 34a- 5p- SNALP treated 
mice.48
CONCLUSIONS
First, miR- 34a- 5p over- expression in immune cells impacts 
the antitumor- response of M1- macrophages, CD4+ and 
CD8+ T cells by downregulation of CXCR3 and its ligands 
CXCL10 and CXCL11. As a result, less immune cells will 
be attracted to the tumor site. Second, miR- 34a- 5p over- 
expression in M1- macrophages, CD4+ and CD8+T cells 
may partly explain the immune- mediated SAEs including 
lymphocytopenia that have been observed in the phase 
I study of the miRNA- 34a- 5p- based cancer therapy. Our 
results favor the idea of intratumor injections of MRX34 
favorably encapsulated in nanocarriers to allow specific 
downregulation of CXCR3 and other oncogenic miR- 
34a- 5p target genes in the cancer cells while avoiding 
systemic SAEs caused by the intravenous administration 
of the miR- 34a- 5p mimic.
Contributors MH, BW- R, AK, EM conceived and designed the experiments. MH, 
LN, BW- R, LK, SR, CD, TT, TK performed the experiments. MH, LN, LK, BW- R, TK 
analyzed the data. MH, BW, MS, HPL, AK, EM contributed to the writing of the 
manuscript.
Funding This work was supported by the European Union’s Seventh Framework 
Program for Research, Technological Development and Demonstration [grant 
number: 600841] and by the Michael J. Fox Foundation [grant number: 14446].
Competing interests No, there are no competing interests.
Patient consent for publication Not required.
Ethics approval The study was carried out according to the Declaration of Helsinki 
and was approved by the local ethics committee (Ref.-No. 213/08). All study 
participants gave written informed consent to participate in this study.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement All data relevant to the study are included in the 
article or uploaded as supplementary information.
Supplemental material This content has been supplied by the author(s). It has 
not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been 
peer- reviewed. Any opinions or recommendations discussed are solely those 
of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and 
responsibility arising from any reliance placed on the content. Where the content 
includes any translated material, BMJ does not warrant the accuracy and reliability 
of the translations (including but not limited to local regulations, clinical guidelines, 
terminology, drug names and drug dosages), and is not responsible for any error 
and/or omissions arising from translation and adaptation or otherwise.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iD
Martin Hart http:// orcid. org/ 0000- 0001- 9361- 8106
REFERENCES
 1 Ambros V, Bartel B, Bartel DP, et al. A uniform system for microRNA 
annotation. RNA 2003;9:277–9.
 2 Engels BM, Hutvagner G. Principles and effects of microRNA- 
mediated post- transcriptional gene regulation. Oncogene 
2006;25:6163–9.
 3 Moretti F, Thermann R, Hentze MW. Mechanism of translational 
regulation by miR-2 from sites in the 5' untranslated region or the 
open reading frame. RNA 2010;16:2493–502.
 4 Garzon R, Calin GA, Croce CM. Micrornas in cancer. Annu Rev Med 
2009;60:167–79.
 5 Li Y, Guessous F, Zhang Y, et al. Microrna- 34A inhibits 
glioblastoma growth by targeting multiple oncogenes. Cancer Res 
2009;69:7569–76.
 6 Ludwig N, Kim Y- J, Mueller SC, et al. Posttranscriptional deregulation 
of signaling pathways in meningioma subtypes by differential 
expression of miRNAs. Neuro Oncol 2015;17:1250–60.
by copyright.
 on A



















13Hart M, et al. J Immunother Cancer 2020;8:e001617. doi:10.1136/jitc-2020-001617
Open access
 7 Bu P, Chen K- Y, Chen JH, et al. A microRNA miR- 34a- regulated 
bimodal switch targets Notch in colon cancer stem cells. Cell Stem 
Cell 2013;12:602–15.
 8 Hong DS, Kang Y- K, Borad M, et al. Phase 1 study of MRX34, a 
liposomal miR- 34a mimic, in patients with advanced solid tumours. 
Br J Cancer 2020;122:1630–7.
 9 Patel D, Boufraqech M, Jain M, et al. Mir- 34A and miR-483- 5p are 
candidate serum biomarkers for adrenocortical tumors. Surgery 
2013;154:1224–9. discussion 29.
 10 Eichelser C, Flesch- Janys D, Chang- Claude J, et al. Deregulated 
serum concentrations of circulating cell- free microRNAs miR-
17, miR- 34a, miR-155, and miR-373 in human breast cancer 
development and progression. Clin Chem 2013;59:1489–96.
 11 Leidinger P, Backes C, Dahmke IN, et al. What makes a blood cell 
based miRNA expression pattern disease specific?--a miRNome 
analysis of blood cell subsets in lung cancer patients and healthy 
controls. Oncotarget 2014;5:9484–97.
 12 Hart M, Rheinheimer S, Leidinger P, et al. Identification of miR- 34a- 
target interactions by a combined network based and experimental 
approach. Oncotarget 2016;7:34288–99.
 13 Diener C, Hart M, Alansary D, et al. Modulation of intracellular 
calcium signaling by microRNA- 34a- 5p. Cell Death Dis 2018;9:1008.
 14 Hart M, Walch- Rückheim B, Friedmann KS, et al. miR- 34A: a new 
player in the regulation of T cell function by modulation of NF-κB 
signaling. Cell Death Dis 2019;10:46.
 15 Hart M, Walch- Rückheim B, Krammes L, et al. miR- 34A as hub of T 
cell regulation networks. J Immunother Cancer 2019;7:187.
 16 Beitzinger M, Peters L, Zhu JY, et al. Identification of human 
microRNA targets from isolated Argonaute protein complexes. RNA 
Biol 2007;4:76–84.
 17 Hart M, Walch- Rückheim B, Friedmann KS, et al. miR- 34A: a new 
player in the regulation of T cell function by modulation of NF-κB 
signaling. Cell Death Dis 2019;10:46.
 18 Gerstner N, Kehl T, Lenhof K, et al. GeneTrail 3: advanced 
high- throughput enrichment analysis. Nucleic Acids Res 
2020;48:W515–20.
 19 Szklarczyk D, Gable AL, Lyon D, et al. String v11: protein- protein 
association networks with increased coverage, supporting functional 
discovery in genome- wide experimental datasets. Nucleic Acids Res 
2019;47:D607–13.
 20 Dweep H, Gretz N. miRWalk2.0: a comprehensive atlas of microRNA- 
target interactions. Nat Methods 2015;12:697.
 21 Chou C- H, Shrestha S, Yang C- D, et al. miRTarBase update 2018: a 
resource for experimentally validated microRNA- target interactions. 
Nucleic Acids Res 2018;46:D296–302.
 22 Tokunaga R, Zhang W, Naseem M, et al. CXCL9, CXCL10, CXCL11/
CXCR3 axis for immune activation - A target for novel cancer 
therapy. Cancer Treat Rev 2018;63:40–7.
 23 Tannenbaum CS, Tubbs R, Armstrong D, et al. The CXC chemokines 
IP-10 and mig are necessary for IL-12- mediated regression of the 
mouse RENCA tumor. J Immunol 1998;161:927–32.
 24 Tensen CP, Flier J, Van Der Raaij- Helmer EM, et al. Human IP-9: a 
keratinocyte- derived high affinity CXC- chemokine ligand for the IP-
10/Mig receptor (CXCR3). J Invest Dermatol 1999;112:716–22.
 25 House IG, Savas P, Lai J, et al. Macrophage- Derived CXCL9 and 
CXCL10 are required for antitumor immune responses following 
immune checkpoint blockade. Clin Cancer Res 2020;26:487–504.
 26 Qian C, An H, Yu Y, et al. Tlr agonists induce regulatory dendritic 
cells to recruit Th1 cells via preferential IP-10 secretion and inhibit 
Th1 proliferation. Blood 2007;109:3308–15.
 27 Schmid H, Boucherot A, Yasuda Y, et al. Modular activation of 
nuclear factor- kappaB transcriptional programs in human diabetic 
nephropathy. Diabetes 2006;55:2993–3003.
 28 Ohmori Y, Schreiber RD, Hamilton TA. Synergy between interferon- 
gamma and tumor necrosis factor- alpha in transcriptional activation 
is mediated by cooperation between signal transducer and 
activator of transcription 1 and nuclear factor kappaB. J Biol Chem 
1997;272:14899–907.
 29 Xu M, Li D, Yang C, et al. Microrna- 34A inhibition of the TLR 
signaling pathway via CXCL10 suppresses breast cancer cell 
invasion and migration. Cell Physiol Biochem 2018;46:1286–304.
 30 Wu X- Z, Zhai K, Yi F- S, et al. IL-10 promotes malignant pleural 
effusion in mice by regulating T
H 1- and TH 17- cell differentiation and 
migration. Eur J Immunol 2019;49:653–65.
 31 Rani MR, Foster GR, Leung S, et al. Characterization of beta- R1, 
a gene that is selectively induced by interferon beta (IFN- beta) 
compared with IFN- alpha. J Biol Chem 1996;271:22878–84.
 32 Weng Y, Siciliano SJ, Waldburger KE, et al. Binding and functional 
properties of recombinant and endogenous CXCR3 chemokine 
receptors. J Biol Chem 1998;273:18288–91.
 33 Cole KE, Strick CA, Paradis TJ, et al. Interferon- Inducible T cell 
alpha chemoattractant (I- TAC): a novel non- ELR CXC chemokine 
with potent activity on activated T cells through selective high affinity 
binding to CXCR3. J Exp Med 1998;187:2009–21.
 34 Gao Q, Wang S, Chen X, et al. Cancer- cell- secreted CXCL11 
promoted CD8+ T cells infiltration through docetaxel- induced- release 
of HMGB1 in NSCLC. J Immunother Cancer 2019;7:42.
 35 Namkoong H, Song M- Y, Seo YB, et al. Enhancement of antigen- 
specific CD8 T cell responses by co- delivery of Fc- fused CXCL11. 
Vaccine 2014;32:1205–12.
 36 Qin S, Rottman JB, Myers P, et al. The chemokine receptors 
CXCR3 and CCR5 mark subsets of T cells associated with certain 
inflammatory reactions. J Clin Invest 1998;101:746–54.
 37 Kim CH, Rott L, Kunkel EJ, et al. Rules of chemokine receptor 
association with T cell polarization in vivo. J Clin Invest 
2001;108:1331–9.
 38 Berchiche YA, Sakmar TP. Cxc chemokine receptor 3 alternative 
splice variants selectively activate different signaling pathways. Mol 
Pharmacol 2016;90:483–95.
 39 Andersson A, Yang S- C, Huang M, et al. Il-7 promotes CXCR3 
ligand- dependent T cell antitumor reactivity in lung cancer. J 
Immunol 2009;182:6951–8.
 40 Yang X, Chu Y, Wang Y, et al. Targeted in vivo expression of IFN- 
gamma- inducible protein 10 induces specific antitumor activity. J 
Leukoc Biol 2006;80:1434–44.
 41 Cambien B, Karimdjee BF, Richard- Fiardo P, et al. Organ- Specific 
inhibition of metastatic colon carcinoma by CXCR3 antagonism. Br J 
Cancer 2009;100:1755–64.
 42 Zhu G, Yan HH, Pang Y, et al. Cxcr3 as a molecular target in breast 
cancer metastasis: inhibition of tumor cell migration and promotion 
of host anti- tumor immunity. Oncotarget 2015;6:43408–19.
 43 Wightman SC, Uppal A, Pitroda SP, et al. Oncogenic CXCL10 
signalling drives metastasis development and poor clinical outcome. 
Br J Cancer 2015;113:327–35.
 44 Sato Y, Motoyama S, Nanjo H, et al. Cxcl10 expression status is 
prognostic in patients with advanced thoracic esophageal squamous 
cell carcinoma. Ann Surg Oncol 2016;23:936–42.
 45 Arenberg DA, White ES, Burdick MD, et al. Improved survival in tumor- 
bearing SCID mice treated with interferon- gamma- inducible protein 10 
(IP-10/CXCL10). Cancer Immunol Immunother 2001;50:533–8.
 46 Misso G, Zarone MR, Lombardi A, et al. Mir- 125B upregulates 
miR- 34a and sequentially activates stress adaption and cell 
death mechanisms in multiple myeloma. Mol Ther Nucleic Acids 
2019;16:391–406.
 47 Scognamiglio I, Di Martino MT, Campani V, et al. Transferrin- 
conjugated SNALPs encapsulating 2'-O- methylated miR- 34a for the 
treatment of multiple myeloma. Biomed Res Int 2014;2014:1–7.
 48 Di Martino MT, Campani V, Misso G, et al. In vivo activity of miR- 34a 
mimics delivered by stable nucleic acid lipid particles (SNALPs) 
against multiple myeloma. PLoS One 2014;9:e90005.
by copyright.
 on A

























sequence                             




































BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) J Immunother Cancer
 doi: 10.1136/jitc-2020-001617:e001617. 8 2020;J Immunother Cancer, et al. Hart M
Supplementary Table 2
















BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) J Immunother Cancer
 doi: 10.1136/jitc-2020-001617:e001617. 8 2020;J Immunother Cancer, et al. Hart M
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) J Immunother Cancer
 doi: 10.1136/jitc-2020-001617:e001617. 8 2020;J Immunother Cancer, et al. Hart M
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) J Immunother Cancer
 doi: 10.1136/jitc-2020-001617:e001617. 8 2020;J Immunother Cancer, et al. Hart M
geneList.ora.zip
WikiPathways
Type Name #Hits Expected score p-Value
enriched Toll-like Receptor Signaling Pathway 17 1.460220 0.000000
enriched Overview of interferons-mediated signaling pathway 11 0.510368 0.000000
enriched Regulation of toll-like receptor signaling pathway 17 1.970590 0.000000
enriched Hepatitis B infection 17 2.140710 0.000000
enriched Cytosolic DNA-sensing pathway 12 1.049090 0.000000
enriched PI3K-Akt Signaling Pathway 19 4.820140 0.000115
enriched Allograft Rejection 8 1.261740 0.007981
enriched Type II interferon signaling (IFNG) 5 0.524545 0.030793
enriched Fibrin Complement Receptor 3 Signaling Pathway 5 0.581252 0.042144
GO - Molecular Function
Type Name #Hits Expected score p-Value
enriched cytokine activity 24 3.033850 0.000000
enriched cytokine receptor binding 23 3.912820 0.000000
enriched type I interferon receptor binding 9 0.226830 0.000000
enriched receptor ligand activity 28 6.592250 0.000000
enriched signaling receptor activator activity 28 6.663140 0.000000
enriched receptor regulator activity 28 7.244390 0.000001
enriched signaling receptor binding 48 21.506300 0.000050
enriched protein binding 201 165.430000 0.001835
enriched deoxycytidine deaminase activity 4 0.113415 0.003383
enriched cytidine deaminase activity 4 0.170123 0.010711
enriched molecular function regulator 45 24.767000 0.013585
enriched phosphatidylserine 1-acylhydrolase activity 3 0.099238 0.045174
GO - Biological Process
Type Name #Hits Expected score p-Value
enriched defense response to virus 30 2.721960 0.000000
enriched defense response 59 15.339400 0.000000
enriched response to external biotic stimulus 58 15.282700 0.000000
enriched response to virus 31 3.955350 0.000000
enriched response to other organism 51 12.390600 0.000000
enriched defense response to other organism 43 9.711160 0.000000
enriched cell surface receptor signaling pathway 78 30.494500 0.000000
enriched immune response 49 13.354600 0.000000
enriched type I interferon signaling pathway 16 0.921497 0.000000
enriched immune system process 76 29.955800 0.000000
enriched regulation of immune system process 58 21.322000 0.000000
enriched natural killer cell activation involved in immune response 10 0.326068 0.000000
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enriched response to exogenous dsRNA 12 0.637960 0.000000
enriched cytokine-mediated signaling pathway 35 9.243330 0.000000
enriched response to organic substance 70 30.537000 0.000000
enriched response to dsRNA 12 0.723021 0.000000
enriched humoral immune response 20 3.005500 0.000000
enriched B cell proliferation 11 0.581252 0.000000
enriched positive regulation of peptidyl-serine phosphorylation of STAT
protein
9 0.283538 0.000000
enriched response to stimulus 126 76.087300 0.000000
enriched natural killer cell activation 11 0.723021 0.000001
enriched positive regulation of immune system process 41 14.106000 0.000001
enriched T cell activation involved in immune response 11 0.779729 0.000001
enriched regulation of cytokine production 33 9.753700 0.000001
enriched leukocyte proliferation 13 1.332630 0.000002
enriched regulation of immune response 40 14.020900 0.000002
enriched lymphocyte proliferation 12 1.148330 0.000003
enriched mononuclear cell proliferation 12 1.162500 0.000004
enriched T cell activation 17 2.877910 0.000007
enriched signal transduction 108 66.730600 0.000017
enriched lymphocyte activation 21 4.820140 0.000018
enriched negative regulation of viral genome replication 10 0.850613 0.000019
enriched B cell differentiation 12 1.403510 0.000020
enriched positive regulation of cytokine production 24 6.294540 0.000020
enriched leukocyte differentiation 19 4.026230 0.000022
enriched regulation of receptor signaling pathway via JAK-STAT 13 1.772110 0.000027
enriched lymphocyte differentiation 16 2.863730 0.000028
enriched positive regulation of metabolic process 86 50.441400 0.000079
enriched regulation of viral genome replication 11 1.360980 0.000105
enriched B cell activation 13 2.084000 0.000134
enriched negative regulation of viral process 11 1.403510 0.000134
enriched positive regulation of immune response 29 9.923820 0.000141
enriched adaptive immune response 16 3.317390 0.000156
enriched innate immune response 22 6.365420 0.000266
enriched cell activation 35 14.063500 0.000308
enriched regulation of cell population proliferation 47 22.470400 0.000456
enriched response to organic cyclic compound 29 10.646800 0.000493
enriched regulation of viral life cycle 12 2.027290 0.000534
enriched pyrimidine nucleoside catabolic process 6 0.326068 0.000683
enriched regulation of protein phosphorylation 43 20.060300 0.000683
enriched positive regulation of protein phosphorylation 34 14.035100 0.000697
enriched positive regulation of phosphorylation 35 14.758100 0.000761
enriched regulation of cellular process 186 148.489000 0.001130
enriched positive regulation of nitrogen compound metabolic process 74 44.288600 0.001158
enriched regulation of signal transduction 73 43.494700 0.001158
enriched positive regulation of peptidyl-serine phosphorylation 10 1.488570 0.001167
enriched positive regulation of protein modification process 38 17.139900 0.001167
enriched response to nitrogen compound 31 12.560700 0.001222
enriched regulation of phosphorylation 45 22.130100 0.001258
enriched positive regulation of cellular metabolic process 76 46.230800 0.001314
enriched response to bacterium 17 4.550780 0.001314
enriched cellular response to lipopolysaccharide 12 2.296660 0.001374
enriched cellular process 228 195.131000 0.001472
enriched cellular response to organic substance 41 19.521600 0.001522
enriched regulation of viral process 13 2.849550 0.002155
enriched cellular response to molecule of bacterial origin 12 2.424250 0.002158
enriched leukocyte activation 30 12.404800 0.002213
enriched locomotion 33 14.503000 0.002614
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enriched negative regulation of cell population proliferation 25 9.512690 0.003225
enriched regulation of signaling 78 49.477300 0.003743
enriched pyrimidine nucleoside metabolic process 6 0.510368 0.004531
enriched positive regulation of protein metabolic process 45 23.746300 0.005673
enriched response to lipopolysaccharide 15 4.153830 0.005673
enriched positive regulation of cellular protein metabolic process 43 22.300200 0.005800
enriched DNA cytosine deamination 4 0.141769 0.005910
enriched regulation of smooth muscle cell proliferation 10 1.899700 0.006257
enriched regulation of peptidyl-serine phosphorylation 10 1.942230 0.007366
enriched regulation of phosphorus metabolic process 46 24.852100 0.007514
enriched regulation of T cell differentiation 10 1.956410 0.007606
enriched blood coagulation 11 2.395890 0.007932
enriched regulation of lymphocyte activation 18 5.968470 0.008188
enriched coagulation 11 2.424250 0.008557
enriched regulation of body fluid levels 17 5.443920 0.008584
enriched response to molecule of bacterial origin 15 4.380660 0.008744
enriched cytidine deamination 4 0.170123 0.009167
enriched cytidine to uridine editing 4 0.170123 0.009167
enriched hemostasis 11 2.480950 0.009819
enriched regulation of T cell activation 15 4.451540 0.009919
enriched positive regulation of cytokine biosynthetic process 7 0.949851 0.011640
enriched cell motility 29 13.170300 0.011709
enriched inflammatory response 18 6.209470 0.011709
enriched response to cytokine 21 7.981590 0.011709
enriched DNA deamination 4 0.198476 0.013597
enriched negative regulation of immune system process 18 6.308710 0.013597
enriched regulation of hemopoiesis 18 6.294540 0.013597
enriched regulation of secretion 26 11.299000 0.013597
enriched chemotaxis 15 4.650020 0.014031
enriched nucleobase-containing small molecule catabolic process 6 0.680490 0.014031
enriched regulation of interferon-beta production 6 0.680490 0.014031
enriched positive regulation of cell population proliferation 28 12.759200 0.015129
enriched positive regulation of interferon-beta production 5 0.425306 0.015536
enriched regulation of cell differentiation 45 25.249000 0.016646
enriched regulation of protein secretion 18 6.478840 0.017442
enriched regulation of leukocyte migration 11 2.736140 0.018695
enriched negative regulation of single stranded viral RNA replication via
double stranded DNA intermediate
4 0.226830 0.019124
enriched regulation of metabolic process 121 91.497600 0.020707
enriched positive regulation of protein secretion 13 3.799400 0.021572
enriched cellular response to exogenous dsRNA 4 0.241007 0.021705
enriched negative regulation of cytokine production 13 3.827760 0.021705
enriched positive regulation of secretion 17 6.053530 0.021705
enriched regulation of cytokine biosynthetic process 8 1.474400 0.021705
enriched regulation of establishment of protein localization 24 10.448400 0.021705
enriched regulation of locomotion 29 13.808300 0.021705
enriched regulation of protein transport 23 9.782050 0.021705
enriched regulation of lymphocyte differentiation 10 2.381720 0.024208
enriched cell migration 26 11.894400 0.024242
enriched cell population proliferation 19 7.343630 0.024242
enriched B cell receptor signaling pathway 5 0.496191 0.025247
enriched positive regulation of chemokine production 6 0.793905 0.025247
enriched cellular response to cytokine stimulus 17 6.195300 0.026358
enriched regulation of interleukin-6 production 9 1.970590 0.026435
enriched positive regulation of striated muscle cell differentiation 6 0.822259 0.028908
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enriched regulation of protein localization 29 14.247800 0.031595
enriched regulation of sarcomere organization 3 0.099238 0.031918
enriched DNA demethylation 4 0.283538 0.033448
enriched regulation of angiogenesis 13 4.068770 0.034268
enriched positive regulation of peptide secretion 13 4.082940 0.035099
enriched positive regulation of establishment of protein localization 17 6.436300 0.037481
enriched base conversion or substitution editing 4 0.297715 0.037594
enriched cellular response to dsRNA 4 0.297715 0.037594
enriched regulation of cell activation 19 7.683870 0.037594
enriched positive regulation of apoptotic process 21 9.002320 0.038551
enriched positive regulation of protein transport 16 5.897580 0.040247
enriched regulation of muscle cell differentiation 9 2.126530 0.040247
enriched regulation of cellular protein metabolic process 57 36.377900 0.040870
enriched positive regulation of cell death 22 9.739520 0.041330
enriched positive regulation of programmed cell death 21 9.073210 0.041330
enriched demethylation 6 0.921497 0.045042
enriched negative regulation of transposition 4 0.326068 0.048107
Reactome - Pathways
Type Name #Hits Expected score p-Value
enriched Interferon alpha/beta signaling 16 0.949851 0.000000
enriched Regulation of IFNA signaling 10 0.368599 0.000000
enriched TRAF6 mediated IRF7 activation 10 0.411130 0.000000
enriched Factors involved in megakaryocyte development and platelet
production
11 1.545280 0.000113
enriched Formation of the Editosome 3 0.127592 0.041282
enriched mRNA Editing: C to U Conversion 3 0.127592 0.041282
GO - Cellular Component
Type Name #Hits Expected score p-Value
enriched extracellular region 51 25.078900 0.001130
enriched extracellular space 41 20.131200 0.007170
enriched external side of plasma membrane 14 4.012060 0.025875
KEGG - Pathways
Type Name #Hits Expected score p-Value
enriched Influenza A 20 2.395890 0.000000
enriched Toll-like receptor signaling pathway 17 1.488570 0.000000
enriched Hepatitis B 18 2.296660 0.000000
enriched Measles 17 1.956410 0.000000
enriched Cytokine-cytokine receptor interaction 23 4.182180 0.000000
enriched RIG-I-like receptor signaling pathway 13 0.992382 0.000000
enriched Autoimmune thyroid disease 11 0.737198 0.000000
enriched Hepatitis C 16 2.197420 0.000000
enriched Jak-STAT signaling pathway 16 2.296660 0.000000
enriched Cytosolic DNA-sensing pathway 11 0.893144 0.000000
enriched Natural killer cell mediated cytotoxicity 14 1.842990 0.000001
enriched Kaposi sarcoma-associated herpesvirus infection 16 2.636900 0.000002
enriched Necroptosis 15 2.310830 0.000002
enriched Epstein-Barr virus infection 16 2.835380 0.000004
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enriched Human cytomegalovirus infection 16 3.189800 0.000016
enriched PI3K-Akt signaling pathway 20 5.004440 0.000016
enriched NOD-like receptor signaling pathway 14 2.551840 0.000029
enriched Human immunodeficiency virus 1 infection 15 2.991320 0.000032
enriched Human papillomavirus infection 17 4.664190 0.000341
enriched Transcriptional misregulation in cancer 12 2.622720 0.000885
enriched Herpes simplex virus 1 infection 20 6.946670 0.001346
enriched Tuberculosis 11 2.509310 0.002541
enriched Pathways in cancer 20 7.499570 0.003385
enriched Graft-versus-host disease 5 0.581252 0.014473
enriched Viral protein interaction with cytokine and cytokine receptor 7 1.417690 0.024144
enriched TNF signaling pathway 7 1.587810 0.043295
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geneList.ora.zip
WikiPathways
No significant categories have been found.
GO - Molecular Function
Type Name #Hits Expected score p-Value
depleted nucleic acid binding 15 35.418900 0.026638
GO - Biological Process
No significant categories have been found.
Reactome - Pathways
No significant categories have been found.
GO - Cellular Component
No significant categories have been found.
KEGG - Pathways
No significant categories have been found.
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GeneSymbol RefSeqAccession
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